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Background and Purpose—White matter hyperintensities (WMH) are associated with decline in cognition, gait, mood,
and urinary continence. Associations may depend on the method used for measuring WMH. We investigated the ability
of different WMH scoring methods to detect differences in WMH load between groups with and without symptoms.
Methods—We used data of 618 independently living elderly with WMH collected in the Leukoaraiosis And DISability
(LADIS) study. Subjects with and without symptoms of depression, gait disturbances, urinary incontinence, and
memory decline were compared with respect to WMH load measured qualitatively using 3 widely used visual rating
scales (Fazekas, Scheltens, and Age-Related White Matter Changes scales) and quantitatively with a semiautomated
volumetric technique and an automatic lesion count. Statistical significance between groups was assessed with the 2
and Mann–Whitney tests. In addition, the punctate and confluent lesion type with comparable WMH volume were
compared with respect to the clinical data using Student t test and 2 test. Direct comparison of visual ratings with
volumetry was done using curve fitting.
Results—Visual and volumetric assessment detected differences in WMH between groups with respect to gait disturbances
and age. WMH volume measurement was more sensitive than visual scores with respect to memory symptoms. Number
of lesions nor lesion type correlated with any of the clinical data. For all rating scales, a clear but nonlinear relationship
was established with WMH volume.
Conclusions—Visual rating scales display ceiling effects and poor discrimination of absolute lesion volumes. Conse-
quently, they may be less sensitive in differentiating clinical groups. (Stroke. 2006;37:836-840.)
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White matter hyperintensities (WMH) on MRI are associ-ated with cognitive dysfunction, gait abnormalities, falls,
and depression and contribute to disability in the elderly popu-
lation.1–5 Lesion load on MRI may serve as surrogate marker of
disease burden and may ultimately guide treatment. For the
measurement of WMH extent, different methods can be used,
ranging from visual rating to fully computerized techniques.
Visual rating of WMH is easy, and several scales are available
with good reproducibility.6 The visual scales often do not detail
size and location, and most are not linear. Scores from different
rating scales are not directly comparable.7 Most volumetric
studies use supervised semiautomated methods that may provide
more information on location and size, as well as continuous
data, but are time consuming.8,9 Both methods have been used to
correlate WMH with clinical data and have rendered varying
results.10,11 Subjective memory symptoms, although difficult to
define, are associated with higher risk of dementia and WMH
and may be used for the early detection of subjects at risk.12
Number of lesions and lesion pattern (punctate versus conflu-
ent) may also be correlated to clinical data. WMH burden might
be caused by a large number of punctate lesions or few confluent
lesions, possibly leading to different clinical signs.
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In this study, we aimed to establish cross-sectionally the
sensitivity of several visual WMH scales, volumetric WMH
measurement, as well as WMH lesion count and pattern, to
symptoms of cognitive decline, gait abnormalities, urinary
incontinence, and depression. The relationship between vi-
sual and volumetric methods was characterized by establish-
ing the mathematical function that best fitted the data. The
study group consisted of elderly independently living indi-
viduals recruited on the basis of WMH and stratified by
lesion severity into 3 groups.
Materials and Methods
Subjects
Data were drawn from the multinational multicenter longitudinal
Leukoaraiosis And DISability (LADIS) study among 639 elderly,
described previously.13 Inclusion criteria were 65 to 85 years of age
and no or mild disability in everyday life (as established with the
Instrumental Activities of Daily Living scale).14 Subjects were
required to have at least some degree of WMH, demonstrated on
MRI. Participants presented for evaluation in various settings: stroke
unit, memory clinic, neurological or geriatric wards/clinic, popula-
tion studies on aging, controls in other studies.
The study was approved by the local ethics committees, and all
subjects gave informed consent. At baseline, subjects underwent a
standardized evaluation (including global functioning, cognitive,
motor, and psychiatric assessment), and, together with their infor-
mants, filled in questionnaires on medical history.
The data used in this study are age, gender, presence of depression
requiring therapy, symptoms of urinary incontinence, gait distur-
bances, and memory problems, as expressed by the participants or
their informants.
MRI Scans
All subjects underwent magnetic resonance scanning following a
standard protocol, during which 0.5-T or 1.5-T scanners were used
and series included axial T2-weighted images (echo time [TE] 100 to
120 ms; repetition time [TR] 4000 to 6000 ms; voxel size 115 to
7.5 mm3; 19 to 24 slices), axial fluid-attenuated inversion recovery
(FLAIR) images (TE 100 to 140 ms; TR 6000 to 10 000 ms;
inversion time 2000 to 2400 ms; voxel size 115 to 7.5 mm3; 19
to 24 slices), and coronal or sagittal 3D T1 sequence (TE 4 to 7 ms;
TR 10 to 25 ms; flip angle 15 to 30°; voxel size 111 to 1.5 mm3).
All scans were checked and stored at the Image Analysis Center of
the VU Medical Center, Amsterdam, the Netherlands. Postprocess-
ing and data analysis for this study was performed in Amsterdam and
Copenhagen. Of the 639 scans, 21 could not be used because of
insufficient quality for the volumetric assessment.
Visual Rating
On the FLAIR images, we applied the visual rating scales of Fazekas
(range 0 to 3), Scheltens (range 0 to 84), and the Age-Related White
Matter Changes (ARWMC) scale (range 0 to 30).15–17 All ratings were
performed by an experienced rater (E.vS.) blind to the clinical data.
Volumetric Assessment
Volumetric analysis of WMH was performed by a single rater on the
same axial FLAIR images, including the infratentorial region, using a
Sparc 5 workstation (SUN). Lesions were marked and borders were set
using local thresholding (home-developed software Show_Images, ver-
sion 3.6.1) on each slice. No distinction was made between subcortical
and periventricular hyperintensities. Areas of hyperintensity on T2-
weighted images around infarctions and lacunes were disregarded.
Lesion Count
An automated assessment of the number of lesions was performed by
defining each lesion that was generated with the volumetric method,
as a cluster of 3D connected voxels, and counting the number of such
clusters (26-connectivity).
Reliability Assessment
To test reproducibility of the different methods, 18 scans, with a
mean volume (SD) of 26.3 (19.0) mL, were assessed twice with an
interval of 2 months.
Statistical Analysis
Sensitivity of WMH measurements to detect clinical group differ-
ences was tested with 2 for trend (Fazekas scale) and Mann–
Whitney test (Scheltens scale, ARWMC scale, volumetric measure-
ment, and lesion count). Nonparametric testing was used for the
WMH volumes because of the nonnormal distribution. Differences
in lesion volume and number between Fazekas groups were tested
using ANOVA with Bonferroni correction.
To test the hypothesis that lesion type (punctate, defined as
Fazekas score 1, versus confluent, defined as Fazekas score 3, with
comparable lesion volumes) was associated with clinical character-
istics, we selected all subjects with WMH volume between 15 and 30
mL. In this volume range, both Fazekas scores 1 and 3 were
represented. These groups were compared with respect to the clinical
data, using the Student t test and 2 test.
Visual rating scales were correlated with the volumetric method using
Spearman rank correlation method. To test the hypothesis of a nonlinear
relationship between the visual methods and the volumetric method, we
fitted a linear and a quadratic function to the plot using a linear
regression with a correction factor based on the local variance.18
Results
WMH Load and Clinical Data
Table 1 shows mean WMH volumes and scores for different
subject groups. Mean WMH volumes, but not visual ratings,
were significantly greater in men than in women. Both visual
and volumetric assessments showed group differences in WMH
load between the older and younger subjects. No significant
differences in WMH load could be found between the groups
with and without a history of depression or symptoms of urinary
incontinence. The mean WMH load of subjects with symptoms
of gait disturbance was only significantly larger when measured
volumetrically or with the ARWMC and Scheltens scales. With
the volumetric assessment only, we were able to establish a
significant difference in lesion load between subjects with and
without memory symptoms.
Mean Lesion Volume and Lesion Count
Fazekas score 1 corresponded to a mean lesion volume of
0.20 mL, score 2 to 0.45 mL per lesion and score 3 to 1.26 mL
per lesion (Table 2). The differences were statistically signif-
icant between all groups. Table 2 also shows mean total
WMH for each Fazekas category, which was also statistically
significant between the groups. Subjects in the Fazekas score
2 category tended to have most lesions. Number of lesions did
not discriminate significantly between groups with and with-
out symptoms (Table 1).
Lesion Pattern
We found no significant differences in clinical features
between the groups with punctate (Fazekas 1) and confluent
(Fazekas 3) lesions (Table 3).
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Correlation Between Visual Rating Scales and
Volumetric Measurement
Scatter plots for the Fazekas and ARWMC scales with WMH
volume are shown in Figures 1 and 2. The scatter and shape
of the plot for the Scheltens score was similar to the scatter
plot of the ARWMC score (data not shown). Increasing
volume correlated with higher visual scores (Spearman 
0.86), and scatter increased with higher WMH visual scores.
The relationship with WMH volume was better described by
a quadratic than a linear model, indicated by higher R2 (Table
4). When corrected for difference in variance, the difference
between the linear and quadratic model was statistically
significant (P0.01).
Intraobserver Reliability
Intrarater agreement for the scales was good with a  for
Fazekas score of 0.84. Intraclass correlation coefficients were
0.93 (ARWMC scale), 0.92 (Scheltens scale), and 0.99
(volume measurement). The mean difference between the 2
measurements was not statistically significant when tested
against 0 using a 1-sample t test.
Discussion
The results indicate that volumetry may be more sensitive to
detect small group differences. This is in line with previous
research, correlating WMH measurement methods with cogni-
tive performance.10 Subjective and objective memory symptoms
are not interchangeable for the assessment of cognition, but both
seem to be related with WMH. The best method for the
measurement of WMH with respect to objective cognitive
measures is still to be established.
The ARWMC and Scheltens rating scales have a greater
range than the Fazekas scale and were found to differentiate
better between groups. This finding corresponds with a review
on the relationship between WMH and cognition.19 The Fazekas
scale seems most appropriate for defining different WMH
groups. No group differences were detected for symptoms of
urinary incontinence and depression. One of the reasons could
TABLE 2. Lesion Characteristics for Each Fazekas Category
Fazekas 1 Fazekas 2 Fazekas 3
Mean volume per lesion, mL (SD)† 0.20 (0.1) 0.45 (0.4) 1.26 (1.0)
Mean WMH volume, mL (SD)† 6.49 (4.7) 18.83 (7.7) 51.35 (26.1)
Mean no. of lesions (SD)† 33.2 (18) 53.6 (25) 51.0 (24)
TABLE 3. Differences in a Group of Subjects With WMH
Volume 15–30 mL
Fazekas 1 Fazekas 3 P Value
Total subjects 17 29
Mean age, y 74.4 73.2 0.47*
% Male 58.8 37.9 0.2†
% History of depression 29.4 27.6 0.9†
% Urinary incontinence complaints 29.4 20.7 0.5†
% Gait disturbance complaints 41.2 62.1 0.1†
% Memory complaints 82.4 58.6 0.1†
*Student t test; †2.













Male 278 25.0 (26.6) 1.9 (0.8) 9.9 (5.9) 18.4 (9.4) 43.0 (23.1)
Female 340 18.1 (18.2)** 1.7 (0.8) 9.6 (5.5) 18.0 (8.9) 44.5 (24.5)
Age groups
65–74 y 315 17.6 (19.4) 1.7 (0.8) 9.1 (5.5) 17.0 (9.0) 42.8 (23.8)
75–85 y 303 24.9 (25.1)** 1.9 (0.8)** 10.5 (5.8)** 19.3 (9.1)** 44.8 (23.9)
History of depression
Yes 170 21.5 (22.8) 1.8 (0.8) 10.1 (5.7) 18.7 (9.7) 45.8 (26.3)
No 448 21.1 (22.6) 1.8 (0.8) 9.6 (5.6) 18.0 (8.9) 43.0 (22.8)
Complaints of urine
incontinence
Yes 124 23.1 (23.0) 1.8 (0.8) 10.4 (5.7) 19.0 (9.2) 45.4 (24.9)
No 494 20.7 (22.6) 1.8 (0.8) 9.6 (5.7) 18.0 (9.1) 43.4 (23.6)
Complaints of gait
disturbances
Yes 255 24.7 (25.2) 1.9 (0.8) 10.6 (5.9) 19.7 (9.5) 46.5 (26.3)
No 355 18.6 (20.4)** 1.7 (0.8) 9.1 (5.5)** 17.0 (8.7)** 41.9 (21.8)
Not applicable 8 21.7 (17.5) 1.8 (0.8) 9.8 (4.5) 18.1 (8.4) 42.3 (26.3)
Memory complaints
Yes 393 22.1 (23.0) 1.8 (0.8) 9.9 (5.7) 18.4 (9.1) 45.4 (24.7)
No 225 19.5 (21.9)* 1.8 (0.8) 9.6 (5.7) 17.8 (9.1) 41.1 (23.9)
†Mann–Whitney test; ‡2 for trend; *P0.05; **P0.01.
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be that only WMH in certain areas correlate with these symp-
toms. Frontal WMH has been associated with mood disorders,
cognitive functions, and gait problems. On the other hand, it was
shown that WMH in different regions are highly correlated and
that their influence on clinical signs may therefore not be limited
to certain areas of the brain.20
To our knowledge, this is the first report on lesion count as
a measure of WMH severity. We found that it was not
sensitive to detect associations with clinical signs, possibly
because lesion count does not take into account lesion size. In
progressing disease, lesions can merge, leading to a smaller
total number of lesions. Few lesions could therefore indicate
either mild or severe disease. This lack of correlation between
number of lesions and clinical findings was also found in
individuals with multiple sclerosis (MS). This caused studies
in MS to focus on total T2 lesion volume and T1 gadolinium
enhancing lesions instead of number of lesions.21,22
We compared subjects with punctiforme and confluent lesion
patterns who had comparable WMH volumes. We found no
differences in symptoms between the groups. Although these
subanalyses limited the number of subjects studied, it illustrates
the arbitrary nature of the qualitative scoring system.
We confirmed the good correlations between all 3 visual
rating scales and the WMH volume, but the current study shows
that the variability in WMH volume is large in the patient groups
with high visual scores.23 Subject group with higher visual
scores contains subjects with different degrees of WMH burden,
leading to decreased correlation with clinical data. When pro-
gression of WMH is measured, this ceiling effect can be even
greater. A previous study on the detection of WMH progression
with conventional visual rating scales showed lack of sensitivity
compared with WMH volume measurement.24 This effect is
especially of interest because WMH progression seems to occur
fastest in patients with a high lesion load.25
The WMH volume in this study was significantly higher than
reported in previous studies.26,27 The LADIS study was designed
to enroll a large population of subjects with WMH, and partic-
ipants were stratified into 3 categories of WMH severity. This
approach is different from population-based studies and resulted
in a relatively large group of subjects with a high WMH lesion
load. Results are therefore not directly applicable to the healthy
elderly population. The advantage of this design is the possibility
of studying a broad spectrum of lesion loads.
WMH burden can be presented as volume or as a proportion
of the total white matter or intracranial volume, depending on the
focus of the study. This makes comparison between studies
complicated. We did not correct for intracranial volume or white
matter volume because we wanted to compare the raw volumes
with visual scales that are also uncorrected. Wen and Sachdev
investigated uncorrected WMH volume and found no differ-
ences in WMH volumes between men and women, whereas in
our study, men had a larger mean WMH volume than women.27
The subjects in their study were younger than our study
participants (60 to 64 years versus 65 to 85 years), which could
partly explain this difference.
We did not control for risk factors for WMH such as
hypertension. In addition, objective measures for cognition,
gait, depression, and urinary incontinence were also not
included here. This was done because the focus of this study
was not to establish a causal relationship of WMH with
clinical data but a comparison between scoring methods in
their association with symptoms, which is clearly of clinical
relevance for clinicians dealing with these patients.
Appendix
Participating Centers and Personnel
Helsinki, Finland (Memory Research Unit, Department of Clinical
Neurosciences, Helsinki University): Timo Erkinjuntti, MD, PhD,
TABLE 4. Mathematical Models of the Relationship Between
Visual Rating Scales and WMH Volume
Model R 2
Fazekas scale Linear 0.58
Quadratic 0.62*
ARWMC scale Linear 0.67
Quadratic 0.71*
Scheltens scale Linear 0.60
Quadratic 0.63*
*Difference significant at the 0.01 level.
Figure 1. Scatter plot of WMH volume of each Fazekas
category.
Figure 2. Scatter plot of WMH volume of each ARWMC score.
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